MedTrace completes capital raising of DKK 21 mill.


08. april, 2020

MedTrace Pharma A/S has received new capital to advance its preparations for the upcoming Phase III clinical study. Three new investors, together with existing investors, have added fresh capital into MedTrace and at the same time converted loans into new share capital.

The proceeds extend the company's 'runway' well into 2021 and will furthermore finance the completion of the application to the US Health Authorities (FDA) to initiate the Phase III cardiology study, which will pave the way for clinical use approval in the United States.

MedTrace has already entered two commercial agreements on the use of its prototype equipment and expects to sign three more contracts this year. A total of seven fully functional prototypes have been produced, two of which are installed in Denmark, two in the US, one in Japan, while the last two will be installed in the Netherlands and Sweden within the next 3-6 months.

With new capital and more reputable investors on board MedTrace are proving once again that their technology has the potential to revolutionize the way we scan heart patients today"

- Lene Gerlach, Investment Manager i Vaekstfonden

With the capital raising, MedTrace expects to position themselves even stronger for the upcoming capital raising, which will fund the completion of the Phase III clinical study.

CEO Martin Stenfeldt says:
"Capital raising is a strong reinforcement of the belief in MedTrace's technology and we look forward to continue our development with the new co-owners. We have many exciting initiatives in the pipeline and the new financing will enable the success of some very valuable goals for the company's future."

Chairman of MedTrace Pharma A/S's Board of Directors Ulrik Spork comments:
"It is a great pleasure for the company to be able to welcome new investors on board and to see that existing investors also continue to support the company with fresh capital, especially during a time where other matters takes a lot of attention."

Lene Gerlach Investment Manager i Vaekstfonden:
"MedTrace is a very promising company. With new capital and more reputable investors on board MedTrace are proving once again that their technology has the potential to revolutionize the way we scan heart patients today. I look forward to following MedTrace's development - particularly in the US market"

Seneste nyheder

Ung gruppe af kolleger

Danish tech company completes first investment round: Will open the “black box” of sales call

The Danish tech company Capturi completes its first investment round of a total €11.6M Euro. Capturi has developed a technology that can identify and categorize the good sales arguments in customer conversations, thus opening up a new world of knowledge about conversation techniques that for many companies has so far been a black box. Now the company is ready to go in the market for customers, and together with Vaekstfonden, employees and a number of private investors have additionally joined the investment.



Today we’re launching ‘A Helping Hand’ together with a group of Danish venture investors and industry experts. What is the aim? To help Nordic start-ups adapt to the new normal.

OBI Medical

The global leader in pharmaceutical products and diagnostic tests, Roche, acquires the Danish company OBI Medical ApS

The Swiss company, Roche, has acquired the Danish company OBI Medical in March 2020. Roche is a global leader in pharmaceutical products and diagnostic tests, therefore they saw a potential in the Danish company focusing on developing disruptive blood gas testing technology. OBI Medical has developed a pioneering v-TAC technology that allows for an easier and simpler way to test patients’ blood gas. Today, it is called the Roche v-TAC digital solution and can not only be used to help testing blood gas, but also be a tool to help efficiency in the times of COVID-19 to simplify the monitoring of patients.